NDA 217564 · Takeda Pharms USA
Fruzaqla
Fruquintinib · Oral
NovelPriority reviewCDER novel approval, Nov 8, 2023: To treat refractory, metastatic colorectal cancer
Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Nov 8, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
189
21 Phase 3, 47 recruiting
FAERS reports
3,941
3,790 serious, 1,270 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 31, 2026.
1. INDICATIONS AND USAGE FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. ( 1 )
Mechanism: Fruquintinib is a small molecule kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3 with IC 50 values of 33, 35, and 0.5 nM, respectively. In vitro studies showed fruquintinib inhibited VEGF-mediated endothelial cell proliferation and tubular formation. In vitro and in vivo studies showed fruquintinib inhibited VEGF-induced VEGFR-2 phosphorylation. In vivo studies showed fruquintinib inhibited tumor growth in a tumor xenograft mouse model of colon cancer.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 8, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
2 products under this application
- FRUZAQLA · FRUQUINTINIB 1MG · CAPSULE, ORAL · Prescription
- FRUZAQLA · FRUQUINTINIB 5MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fruquintinib" as an intervention, any sponsor and status, largest first.
- A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal CancerPivotal-lookingCompleted
Hutchison Medipharma LimitedIndustry
NCT04322539 · 691 participants · Start Aug 12, 2020 · Primary completion Jul 29, 2022
Drug: Fruquintinib; Placebo · For: Metastatic Colorectal Cancer; Metastatic Colon Cancer
Sites: Phoenix, Arizona; Tucson, Arizona; Los Angeles, California · 153 sites in all
AskGene Pharma, Inc.Industry
NCT05867420 · 594 participants (planned) · Start Aug 2, 2023 · Primary completion Dec 31, 2026
Drug: ASKG915; Paclitaxel + Bevacizumab and 2 more · For: Advanced Solid Tumors
Sites: New York, New York; Pittsburgh, Pennsylvania; Beijing, China · 4 sites in all
- IBI363 Combined With Bevacizumab for Advanced Colorectal CancerPivotal-lookingRecruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07722494 · 550 participants (planned) · Start Jul 31, 2026 · Primary completion Oct 31, 2028
Drug: IBI363 + bevacizumab; Investigator's choice of therapy · For: Colorectal Cancer
Sites: Wuhan, China; Hangzhou, China
- A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung CancerPivotal-lookingCompleted
Hutchison Medipharma LimitedIndustry
NCT02691299 · 527 participants · Start Dec 9, 2015 · Primary completion Sep 21, 2018
Drug: Fruquintinib; Placebo · For: NSCLC
Sites: Beijing, China; Guangzhou, China; Nantong, China · 11 sites in all
- A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer PatientsPivotal-lookingRecruiting
Chipscreen Biosciences, Ltd.Industry
NCT06497985 · 430 participants (planned) · Start Dec 6, 2024 · Primary completion May 31, 2028
Drug: Tucidinostat; Sintilimab and 2 more · For: Colorectal Cancer
Sites: Guangzhou, China
- A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients (FRESCO)Pivotal-lookingCompleted
Hutchison Medipharma LimitedIndustry
NCT02314819 · 416 participants · Start Dec 2014 · Primary completion Jan 2017
Drug: fruquintinib; placebo · For: Colorectal Cancer
Sites: Hefei, China; Beijing, China; Guangzhou, China · 15 sites in all
- Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial CancerPivotal-lookingRecruiting
HutchmedIndustry
NCT06584032 · 412 participants (planned) · Start Dec 12, 2024 · Primary completion Jan 8, 2029
Drug: fruquintinib; sintilimab and 2 more · For: Advanced Endometrial Cancer
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 17 sites in all
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesPivotal-lookingCompleted
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT04164199 · 404 participants · Start Dec 19, 2019 · Primary completion May 23, 2026
Drug: Tislelizumab; Pamiparib and 11 more · For: Advanced Malignancies
Sites: Miami, Florida; New York, New York; Nashville, Tennessee · 106 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death861
- fatigue482
- colorectal cancer metastatic396
- colon cancer381
- diarrhoea289
- blood pressure increased272
- decreased appetite249
- asthenia246
- myelosuppression244
- dysphonia213
- hypertension199
- off label use190
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 6 |
| 2020 | 11 |
| 2021 | 5 |
| 2022 | 17 |
| 2023 | 59 |
| 2024 | 1,193 |
| 2025 | 1,820 |
| 2026 | 830 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fruzaqla (Fruquintinib)
2024 spending
$137M
Beneficiaries
1,935
5,831 claims
Per beneficiary
$71,042
$935.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $4,562,634 |
| 2024 | $137,466,500 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Dasari A, Lonardi S, Garcia-Carbonero R, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
Li J, Qin S, Xu RH, et al. · JAMA 2018 · Clinical Trial, Phase III, Comparative Study
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2.
Eng C, Dasari A, Lonardi S, et al. · Oncologist 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan.
Kotani D, Yoshino T, Masuishi T, et al. · Int J Clin Oncol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer.
Zhou X, Toms A, Morton D, et al. · J Clin Pharmacol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO.
Dasari A, Eng C, Lonardi S, et al. · Eur J Cancer 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.